Leelamine

Overview

Leelamine is an orally active pyruvate dehydrogenase kinase ( PDK ) inhibitor with an IC 50 value of 9.5 μM, showing a blood glucose lowering effect in the diabetic mouse. Leelamine is also a weak agonist of cannabinoid receptors CB1 and CB2 . Leelamine decreases mitotic activity, prostate-specific antigen expression and induces Apoptosis to cell death in cancer cells.

Application

Products | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Lipid Metabolism | Products > Disease Areas > Colorectal Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Pain | Products > Disease Areas > Glucose Metabolism | Products > Disease Areas > Obesity | Products > Disease Areas > Cancer | Products > Signaling Pathways > Others | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Signaling Pathways > Neuronal Signaling | Products > Signaling Pathways > GPCR/G Protein | Products > Research Areas > Metabolic Disease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Environmental Pollutants | Products > Signaling Pathways > PDK-1 | Products > Signaling Pathways > Cannabinoid Receptor

Product Information

• Catalog No.: HY-W005629
• CAS No.: 1446-61-3
• Molecular Formula: C20H31N
• Molecular Weight: 285.48
• Purity: 95.69%
• Storage: 4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
• Solubility: ≥ 5 mg/mL (17.51 mM); Clear solution
• Availability: In-stock

Source

Original product source